TY - JOUR
T1 - Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31
AU - Agger, Else Marie
AU - Rosenkrands, Ida
AU - Olsen, Anja Weinreich
AU - Hatch, Graham
AU - Williams, Ann
AU - Kritsch, Constantia
AU - Lingnau, Karen
AU - von Gabain, Alexander
AU - Andersen, Claire Swetman
AU - Korsholm, Karen Smith
AU - Andersen, Peter
N1 - Funding Information:
This study was funded by the European Commision (contract no. LSHP-CT-2003-503367). We are grateful that the project was supported by the Austrian Federal Ministry for Economy and Labour as well as by the City of Vienna (WWFF).
PY - 2006/6/29
Y1 - 2006/6/29
N2 - In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.
AB - In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.
KW - Adjuvant
KW - Tuberculosis
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=33744815623&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2006.03.072
DO - 10.1016/j.vaccine.2006.03.072
M3 - Article
C2 - 16675077
AN - SCOPUS:33744815623
SN - 0264-410X
VL - 24
SP - 5452
EP - 5460
JO - Vaccine
JF - Vaccine
IS - 26
ER -
